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Abstract Nephrotic Syndrome is a rare condition asso-
ciated with high morbidity in the 20–40 % of children and
adolescents who fail to respond to standard immunosup-
pressive therapies. Novel non-immunologic mechanisms of
widely used immunosuppressive therapies, as well as
emerging anti-inflammatory drugs, and anti-fibrotics may
play a crucial role in the treatment of patients with
refractory disease. This article will review some of these
treatments and their various stages of investigation.
Key Points
Directed therapies based on specific molecular targets
may replace treatment decisions based on histology
and steroid responsiveness in nephrotic syndrome.
Non-immunologic mechanisms for nephrotic
syndrome therapies are emerging as key in the role
of palliating proteinuric disease.
1 Introduction
Idiopathic nephrotic syndrome affects 1–3 per 100,000
incident patients less than 16 years of age annually [1, 2].
Defined by the triad of proteinuria, hypoalbuminemia, and
hypercholesterolemia, nephrotic syndrome in fact is a
symptom caused by several glomerular disorders that ulti-
mately involve injury to the podocytes, the specialized
epithelial cells of the glomerulus. Primary nephrotic syn-
drome can be categorized by histologic patterns—minimal
change disease (MCD), focal segmental glomerulosclerosis
(FSGS), or membranous glomerulopathy—but clinicians
most often categorize nephrotic syndrome by steroid
responsiveness. The Kidney Disease Improving Global
Outcomes (KDIGO) guidelines published in 2012 provide
evidence-based recommendations for the treatment of chil-
dren with steroid-sensitive and steroid-resistant nephrotic
syndrome [3, 4]. Early studies from the International Study
of Kidney Disease in Children (ISKDC) reported more than
80 % of children with nephrotic syndrome have steroid-re-
sponsive disease with good long-term prognosis [5]. More
contemporary studies suggest the incidence of steroid
resistance may exceed 40 % and is associated with poor
long-term renal prognosis [6]. Unfortunately, 25–40 % of
children and adolescents will be resistant to the standard
therapies of not only steroids, but also cyclophosphamide,
calcineurin inhibitors, and mycophenolate mofetil. The
incidence of steroid-resistant disease is higher in African
Americans, Hispanics, and older children ([12 years of age)
[7, 8]. The need for novel treatments for this population is
substantial. As emerging agents enter various stages of
investigation, it will be important to consider the potential
utility of these treatments in children with difficult-to-treat
nephrotic syndrome (Table 1).
2 Anti-Inflammatory Drugs
Primary nephrotic syndromes are non-inflammatory con-
ditions. The beneficial role of anti-inflammatory drugs like
calcineurin inhibitors for these diseases extends beyond the
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inhibition of interleukin-1 (IL-1) signaling of T lympho-
cytes thought key in the development of increased
glomerular capillary permeability. Interruption of the
podocyte cytoskeleton ultimately leads to injury and flat-
tening (effacement) of podocytes, interruption of the slit
diaphragm and finally proteinuria. Synaptopodin stabilizes
the actin cytoskeleton of the podocyte and is protected
from degradation by phosphorylation. Calcineurin
dephosphorylates synaptopodin, subjecting it to degrada-
tion by cathepsin L. This mechanism impedes calcineurin’s
ability to stabilize the cytoskeleton. Faul et al. [9] showed
that the inhibition of calcineurin by cyclosporine A, pro-
tected against lipopolysaccharide-induced proteinuria in
mice, and demonstrated that activation of calcineurin in the
podocyte is sufficient to cause proteinuria by causing
degradation of synaptopodin. While this example outlines a
novel mechanism of an old drug, new insights on molecular
targets are leading to novel drugs.
2.1 Pentoxifylline
Tumor necrosis factor (TNF)-a is a pro-inflammatory
cytokine that has been demonstrated to be elevated in
patients with nephrotic syndrome [10, 11]. Pentoxifylline is
a nonselective phosphodiesterase inhibitor and methylx-
anthine derivative similar to theophylline that possesses
anti-inflammatory and immunomodulatory effects, and has
been widely used to treat occlusive peripheral vascular
disorders. Studies have demonstrated that pentoxifylline
attenuates nephrotic syndrome secondary to membra-
nous glomerulonephritis, lupus nephritis, and diabetic
nephropathy [12–14]. The anti-proteinuric effect of pen-
toxifylline may be attributed to downregulation of TNF-a
(Fig. 1). Other studies have demonstrated that pentoxi-
fylline’s anti-proteinuric effects may result from the
decrease in urinary monocyte chemoattractant protein 1
(MCP-1), a chemokine that appears to be involved in the
initiation and progression of tubulointerstitial damage in
chronic kidney disease [15–17]. Chen et al. [15] reported a
significant reduction of urinary protein/creatinine ratio in
17 adult patients with proteinuric glomerular disease
(baseline vs. 6 months after pentoxifylline treatment, 2.82
vs. 1.79 g creatinine, p\ 0.006).
2.2 p38 MAPK Signaling: Losmapimod
The major families of MAPK (or mitogen-activated protein
kinases) translate extracellular stimuli to intracellular
responses. The p38 MAPK pathway has been identified as
an important influence within several processes, including
inflammation, differentiation, senescence, tumorogenesis,
and apoptosis. Pro-apoptotic p38 MAPK signaling has been
implicated in both experimental models of renal injury and
in human glomerulopathies. P38 MAPK was found in
podocytes and other glomerular cells after disease induc-
tion [18]. Inhibition of this signaling pathway was effective
in reducing the severity of injury [19]. Podocyte p38
MAPK activation was increased in biopsy samples from
adults with various forms of nephrotic syndrome [20].
These data provide support for the current multicenter,
open-label, phase II, proof-of-mechanism study evaluating
the reduction of proteinuria in individuals with corticos-
teroid or cyclosporine resistant FSGS, when treated with
losmapimod, a p38 MAPK inhibitor (clinicaltrials.gov
NCT02000440).
3 Anti-Fibrotic Drugs
3.1 Endothelin Receptor Type 1A Antagonism:
Sparsentan
Endothelins (ETs) are potent regulators of arterial blood
pressure. Endothelin-1 (ET-1), the only ET expressed in
kidneys, plays a crucial role in cell growth/proliferation,
fluid and electrolyte excretion, vascular tone, and immune
functions. ET-type A1 (ETA1) receptors are located in vas-
cular smooth muscle cells and the endothelial cells of arteries
in the glomerulus, where they promote vasoconstriction and
sodium retention along with cellular proliferation, inflam-
mation, and fibrosis [21]. Signaling crosstalk between
glomerular podocytes and endothelial cells has been identi-
fied as a factor in progressive glomerulosclerosis. SMAD
proteins are condensed protein mediators of transcriptional
activity. Various mechanisms of podocyte injury activate
SMAD proteins associated with ET-1 precursor synthesis
and ET-1 release. Paracrine ET-1/endothelin receptor type A
(EDNRA) signaling causes mitochondrial oxidative damage
and dysfunction in glomerular endothelial cells. Endothelial
mitochondrial DNA damage and dysfunction-dependent
paracrine activities are required for transforming growth
factor beta-1 (TGF-b1)/SMAD-induced podocyte depletion
and segmental glomerulosclerosis with nephrotic syndrome,
elevated serum creatinine, and eventually decreased survival
[22]. The mechanism underlying podocyte apoptosis after
endothelial dysfunction has not been elucidated. Researchers
have also demonstrated the ability to palliate podocyte
effacement and proteinuria in mice with adriamycin-induced
podocyte injury, by using sitaxsentan, a selective ETA1
receptor inhibitor [23]. A randomized, double-blind, active-
control, dose-escalation study with a selective dual-acting
receptor antagonist that has affinity for ETA1 and angio-
tensin II receptors (type 1) is in progress. These investigators
will evaluate the reduction of proteinuria in patients
older than 8 years of age with biopsy-demonstrated FSGS
(clinicaltrials.gov NCT01613118).
3.2 Pirfenidone
Pirfenidone is a novel anti-fibrotic agent that has been
shown to reduce TGF-b1 production and block TNF-alpha
production [24]. Pirfenidone may also have a role in
reducing oxidative stress of renal tubular cells by inhibiting
the mitochondrial apoptotic signaling pathway [25].
Glomerulosclerosis was effectively decreased in diabetic
mice that were given pirfenidone, and in an animal model
of subtotal nephrectomy, pirfenidone intake reduced TGF-
Fig. 1 Emerging therapies for nephrotic syndrome. a Pentoxifylline,
a nonselective phosphodiesterase inhibitor, downregulates TNF-a
release and reduces MCP-1, thereby minimizing the inflammatory
process. b Losmapimod inhibits pro-apoptotic activity of p38 MAPK
in podocytes, resulting in decreased renal fibrosis. c TGF-b1-induced
expression of SMAD proteins stimulates podocyte endothelin-1
release. Endothelin-1 receptor activation stimulates endothelial cell
mitochondrial oxidation damage, which, through unclear mechan-
isms, leads to further podocyte injury and renal fibrosis. Sparsentan,
an endothelin receptor type 1A antagonist inhibits this endothelial
cell-podocyte cross signaling. d Pirfenidone reduces TGF-b1
production, blocks TNF-alpha production, and reduces oxidative
stress of renal tubular cells, making this drug a promising anti-fibrotic
therapy for several glomerular disorders. EDN1 endothelin-1, GBM
glomerular basement membrane, MAPK mitogen-activated protein
kinases, MCP-1 monocyte chemoattractant protein-1, mRNA messen-
ger RNA, TGF-b1 transforming growth factor-b1, TNF tumor
necrosis factor
Table 1 Trial data for
emerging therapies in nephrotic
syndrome
Drug Target Most current study Includes children
Pentoxifylline TNF-alpha Phase III No
Losmapimod p38 MAPK Phase II No
Sparsentan Endothelin type A receptor Phase II Yes
Pirfenidone TGF-beta Phase II No
Rituximab CD20/ SMPDL-3b Phase III Yes
Abatacept B7-1 Pilot Yes
The development of the therapies described in this article remains in various stages of investigation.
Recognition of the importance of including children in these studies is growing
b production with consequently decreased tubulointerstitial
fibrosis [26]. Clinical trials assessing the safety and effi-
cacy of this therapy have been encouraging across multiple
fibrotic conditions, including hepatitis C-associated hep-
atitis, pulmonary fibrosis, and bladder dysfunction due to
multiple sclerosis [27–30]. In an open-label study of 18
patients with FSGS treated with pirfenidone for a median
of 13 months, the rate of glomerular filtration rate (GFR)
decline was slowed by 25 % from a baseline median of
-0.61 ml/min per 1.73 m2 to a median of -0.45 ml/min
per 1.73 m2; p\ 0.01) [31]. Pirfenidone also improved the
estimated GFR (eGFR) in a randomized, placebo-con-
trolled trial of 77 patients with diabetic kidney disease
[mean intergroup difference in eGFR change was 15.5 ml/
min per 1.73 m2 (-2.2 ml/min per 1.73 m2 for placebo vs.
13.3 ml/min per 1.73 m2 for pirfenidone 1200 mg, 95 %
confidence interval 1.1–9.9; p = 0.026)] [32]. There were
no significant differences among study groups in protein-
uria change or urinary TGF-b excretion from baseline to
the end of study. Further studies to understand the potential
clinical role of this therapy are needed.
4 Biologic Agents
4.1 Rituximab
As evidenced by the inclusion in the 2012 KDIGO guide-
lines, rituximab is quickly moving from being classified as
an ‘‘emerging’’ therapy to standard secondary therapy for
steroid-sensitive nephrotic syndrome [3]. The role of B-cell
depletive therapy with rituximab, a chimeric anti-CD20
monoclonal antibody, is yet to be fully determined. A novel
target for rituximab through podocyte sphingomyelinase-
like phosphodiesterase 3b protein (which stabilizes podo-
cyte actin stress fibers and cell survival) has recently
demonstrated an advantageous role for rituximab indepen-
dent of B-cell depletion [33]. Various non-randomized
studies have suggested a favorable response in some
patients with idiopathic nephrotic syndrome. A recent ran-
domized, double-blinded, placebo-controlled trial of 48
children with frequently relapsing steroid-sensitive or
steroid-dependent disease showed a significant difference
[267 vs. 101 relapse free days (Hazard Ratio 0.27,
p\ 0.0001)] for patients who received rituximab versus
placebo, respectively [34]. Studies evaluating the efficacy
of rituximab in patients with steroid- and/or calcineurin
inhibitor-resistant disease have revealed mixed results.
4.2 Abatacept
Protein B7-1 (CD80) is commonly found on antigen pre-
senting cells. This ligand functions as a co-stimulatory
signal for T cells depending on which ligand it binds to.
Binding with CD28 creates a stimulatory signal, while
binding with cytotoxic T lymphocyte associated protein 4
(CTLA-4) promotes a regulatory signal. B7-1 is not
expressed by normal podocytes, but has been found in
human podocytes with various glomerulonephritides
including FSGS and membranoproliferative glomeru-
lonephritis (MPGN). Increased podocyte expression of B7-
1 has additionally been found in mouse models of induced
proteinuria [35, 36]. Yu et al. [36] found that B7-1 influ-
ences podocyte structure and function as increased podo-
cyte migration, and proteinuria was associated with intact
B7-1 expression in their in vitro studies. Their work further
found that B7-1 bound to b1 integrin (an essential ligand to
bind podocytes to the glomerular basement membrane) can
modify the actin cytoskeleton. Abatacept is a fusion protein
of the Fc region of the immunoglobulin IgG1 and extra-
cellular domain of CTLA-4. It blocks CD80 signaling
through competitive binding for T-cell ligands, and has
been proven safe and effective for patients with rheumatoid
arthritis. Yu et al. were not only able to demonstrate in
their in vitro studies that abatacept prevented B7-1-induced
podocyte migration and prevented B7-1/b1 integrin asso-
ciation, they also showed they could induce proteinuric
remission in four patients with recurrent FSGS post
transplant who had failed on rituximab and another patient
with steroid-resistant nephrotic syndrome. While the
authors of this study concluded that B7-1 immunostaining
of biopsies may identify a subgroup of patients who would
benefit from treatment with abatacept, efforts to replicate
these findings have not been widely successful [36].
Nonetheless, this emerging therapy provides an intriguing
option for larger prospective clinical studies.
5 Conclusions
The need for novel therapies in nephrotic syndrome
refractory to standard therapies is substantial. As our
understanding of new molecular targets of both emerging
and old therapies for nephrotic syndrome expand, it will be
important to understand how to safely use these therapies
in children and adolescents, and, therefore, we advocate for
their inclusion in on-going clinical trials.
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